NIGHTINGALE HEALTH OYJ Financials Nightingale Health Oyj
Equities
HEALTH
FI4000490875
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.86 EUR | -4.37% |
|
+18.47% | +66.67% |
| Apr. 16 | Finland’s Nightingale Health Plots US Expansion | MT |
| Apr. 16 | Nightingale Health to Establish A Laboratory in the United States | CI |
Valuation
| Fiscal Period: Giugno | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 345.9 | 108.9 | 52.44 | 112.2 | - | - |
| Enterprise Value (EV) 1 | 237.2 | 16.83 | -26.93 | 46.33 | 60.03 | 112.2 |
| P/E ratio | -21.4 x | -6.95 x | -2.9 x | -6.89 x | -6.89 x | -9.79 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 166 x | 49.4 x | 12.5 x | 23.9 x | 12.9 x | 7.43 x |
| EV / Revenue | 114 x | 7.63 x | -6.44 x | 9.86 x | 6.9 x | 7.43 x |
| EV / EBITDA | -49.9 x | -2.14 x | 2.28 x | -4.73 x | -6.25 x | -17.5 x |
| EV / FCF | -42.5 x | - | 2.29 x | -3.41 x | -4.11 x | -8.44 x |
| FCF Yield | -2.35% | - | 43.6% | -29.4% | -24.3% | -11.9% |
| Price to Book | 2.77 x | 0.99 x | 0.53 x | 1.4 x | 1.75 x | - |
| Nbr of stocks (in thousands) | 59,952 | 60,304 | 60,341 | 60,341 | - | - |
| Reference price 2 | 5.770 | 1.806 | 0.8690 | 1.860 | 1.860 | 1.860 |
| Announcement Date | 9/15/21 | 9/29/22 | 9/28/23 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: June | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | 2.081 | 2.205 | 4.182 | 4.7 | 8.7 | 15.1 |
| EBITDA 1 | -4.752 | -7.846 | -11.84 | -9.8 | -9.6 | -6.4 |
| EBIT 1 | -5.222 | -11.08 | -18.52 | -17.8 | -17.6 | -13.1 |
| Operating Margin | -250.94% | -502.72% | -442.95% | -378.72% | -202.3% | -86.75% |
| Earnings before Tax (EBT) 1 | - | -15.42 | -18.07 | -16.3 | -16.7 | -12.4 |
| Net income 1 | - | -15.38 | - | -16.4 | -16.7 | -11.8 |
| Net margin | - | -697.32% | - | -348.94% | -191.95% | -78.15% |
| EPS 2 | -0.2700 | -0.2600 | -0.3000 | -0.2700 | -0.2700 | -0.1900 |
| Free Cash Flow 1 | -5.582 | - | -11.74 | -13.6 | -14.6 | -13.3 |
| FCF margin | -268.24% | - | -280.8% | -289.36% | -167.82% | -88.08% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 9/15/21 | 9/29/22 | 9/28/23 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: June | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1.013 | 1.068 | 1.322 | 0.884 | 2.243 | 1.939 | 1.715 | 3 |
| EBITDA 1 | - | -2.601 | -3.254 | -4.592 | -5.463 | -6.372 | -5.336 | -4.5 |
| EBIT 1 | - | -2.883 | -4.78 | -6.305 | -8.672 | -9.852 | -9.306 | -8.5 |
| Operating Margin | - | -269.94% | -361.57% | -713.24% | -386.63% | -508.1% | -542.62% | -283.33% |
| Earnings before Tax (EBT) 1 | - | - | -5.062 | -10.36 | -8.547 | - | -8.502 | -7.8 |
| Net income 1 | -3.005 | - | -5.063 | - | -8.553 | - | -8.529 | -7.8 |
| Net margin | -296.64% | - | -382.98% | - | -381.32% | - | -497.32% | -260% |
| EPS 2 | - | - | -0.0900 | -0.1700 | -0.1400 | -0.1600 | -0.1400 | -0.1300 |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/15/21 | 9/15/21 | 2/24/22 | 9/29/22 | 3/23/23 | 9/28/23 | 3/7/24 | - |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 109 | 92.1 | 79.4 | 65.9 | 52.2 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -5.58 | - | -11.7 | -13.6 | -14.6 | -13.3 |
| ROE (net income / shareholders' equity) | -16.8% | -13.1% | -17.3% | -18.4% | -23% | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share 2 | 2.080 | 1.820 | 1.630 | 1.330 | 1.060 | - |
| Cash Flow per Share 2 | -0.0700 | - | -0.1400 | -0.1600 | -0.1700 | - |
| Capex 1 | 4.73 | - | 4.41 | 3.7 | 4 | 4.5 |
| Capex / Sales | 227.44% | - | 105.55% | 78.72% | 45.98% | 29.8% |
| Announcement Date | 9/15/21 | 9/29/22 | 9/28/23 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.86
EUR
Average target price
1.25
EUR
Spread / Average Target
-32.80%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +66.67% | 120M | |
| +4.36% | 32.47B | |
| +14.14% | 7.45B | |
| +22.93% | 3.89B | |
| -16.29% | 3.15B | |
| -25.96% | 1.28B | |
| -36.14% | 1.09B | |
| -0.13% | 893M | |
| -35.42% | 902M | |
| -24.12% | 857M |
- Stock Market
- Equities
- HEALTH Stock
- Financials Nightingale Health Oyj
